Sohrabi Catrin, Foster Andrew, Tavassoli Ali
School of Chemistry, University of Southampton, Southampton, UK.
Curve Therapeutics, University of Southampton, Southampton, UK.
Nat Rev Chem. 2020 Feb;4(2):90-101. doi: 10.1038/s41570-019-0159-2. Epub 2020 Jan 17.
Drug discovery has traditionally focused on using libraries of small molecules to identify therapeutic drugs, but new modalities, especially libraries of genetically encoded cyclic peptides, are increasingly used for this purpose. Several technologies now exist for the production of libraries of cyclic peptides, including phage display, mRNA display and split-intein circular ligation of peptides and proteins. These different approaches are each compatible with particular methods of screening libraries, such as functional or affinity-based screening, and screening in vitro or in cells. These techniques allow the rapid preparation of libraries of hundreds of millions of molecules without the need for chemical synthesis, and have therefore lowered the entry barrier to generating and screening for inhibitors of a given target. This ease of use combined with the inherent advantages of the cyclic-peptide scaffold has yielded inhibitors of targets that have proved difficult to drug with small molecules. Multiple reports demonstrate that cyclic peptides act as privileged scaffolds in drug discovery, particularly against 'undruggable' targets such as protein-protein interactions. Although substantial challenges remain in the clinical translation of hits from screens of cyclic-peptide libraries, progress continues to be made in this area, with an increasing number of cyclic peptides entering clinical trials. Here, we detail the various platforms for producing and screening libraries of genetically encoded cyclic peptides and discuss and evaluate the advantages and disadvantages of each approach when deployed for drug discovery.
传统上，药物发现主要集中于利用小分子文库来鉴定治疗性药物，但新的方法，尤其是基因编码环肽文库，正越来越多地用于此目的。目前存在多种用于生产环肽文库的技术，包括噬菌体展示、mRNA展示以及肽和蛋白质的分裂内含子环化连接。这些不同的方法各自与特定的文库筛选方法兼容，例如基于功能或亲和力的筛选，以及体外或细胞内筛选。这些技术能够在无需化学合成的情况下快速制备包含数亿个分子的文库，因此降低了生成和筛选给定靶点抑制剂的门槛。这种易用性与环肽支架的固有优势相结合，产生了一些难以用小分子药物靶向的靶点的抑制剂。多项报告表明，环肽在药物发现中是一种优势支架，特别是针对诸如蛋白质-蛋白质相互作用等“不可成药”靶点。尽管从环肽文库筛选中获得的命中化合物在临床转化方面仍存在重大挑战，但该领域仍在不断取得进展，越来越多的环肽进入临床试验。在此，我们详细介绍生产和筛选基因编码环肽文库的各种平台，并讨论和评估每种方法在用于药物发现时的优缺点。
